Prognostic significance of CXCR7 in cancer patients: a meta-analysis

BackgroundCXC chemokine receptor 7 (CXCR7) is frequently overexpressed in a variety of tumors. Nevertheless, whether CXCR7 can be used as a tumor prognosis marker has not been systematically assessed. The current meta-analysis was performed to obtain an accurate evaluation of the relationship between CXCR7 level and the prognosis of cancer patients.MethodsEmbase, Web of Science, and PubMed were systematically searched according to a defined search strategy up to June 11, 2018. Then, the required data were extracted from all qualified studies which were screened out based on the defined inclusion and exclusion criteria. Finally, the hazard ratios (HR) with 95% confidence intervals (CI) were used to evaluate the prognostic significance of CXCR7 in tumor patients.ResultsA total of 28 original research studies comprising 33 cohorts and 5685 patients were included in this meta-analysis. The results showed that CXCR7 overexpression was significantly related to worse overall survival (OS) (HR 1.72; 95% CI 1.49-1.99), disease-free survival (DFS) (HR 5.58; 95% CI 3.16-9.85), progression-free survival (PFS) (HR 2.83; 95% CI 1.66-4.85) and recurrence-free survival (RFS) (HR 1.58; 95% CI 1.34-1.88) in cancer patients. Furthermore, for certain types of cancer, significant associations between higher CXCR7 expression and worse OS of glioma (HR 1.77; 95% CI 1.43-2.19), breast cancer (HR 1.45; 95% CI 1.28-1.63), esophageal cancer (HR 2.72; 95% CI 1.11-6.66) and pancreatic cancer (HR 1.46; 95% CI 1.12-1.90) were found. However, for lung cancer and hepatocellular cancer, there was no significant relationship between CXCR7 expression level and OS, (HR 2.40; 95% CI 0.34-17.07) and (HR 1.37; 95% CI 0.84-2.24) respectively.ConclusionsIncreased CXCR7 level could predict poor prognosis of tumor patients and might be regarded as a novel prognostic biomarker for tumor patients.